Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × GSK2110183 × Clear all

Phase

Phase 2 3 Phase 1 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 407 Cyclophosphamide 389 Carboplatin 305 Gemcitabine 282 Nivolumab 275 Paclitaxel 274 Cisplatin 250 Radiotherapy 225 Bevacizumab 208 Dexamethasone 206 Docetaxel 186 fludarabine 184 Rituximab 181 Capecitabine 169 Oxaliplatin 157 Lenalidomide 155 Fluorouracil 151 Temozolomide 136 Cytarabine 134 Etoposide 128 Irinotecan 124 Cetuximab 122 fludarabine phosphate 118 Injections 118 venetoclax 115 Doxorubicin 114 Ipilimumab 112 Azacitidine 108 130-nm albumin-bound paclitaxel 107 atezolizumab 106

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01653912 2018-04-02

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Accenture

Phase 1/2 Completed

59 enrolled 18 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡